Skip to main content
SpringerLink
Log in

The Value of Anti-angiogenics in Bladder Cancer Therapy

  • Living reference work entry
  • First Online:
Tumor Angiogenesis

Abstract

The therapy of metastatic bladder cancer (BC) mainly relies on platinum-based chemotherapy with very limited options like vinflunine in the second line. Therefore, there has not been much change in the median survival of this patient cohort within the last decades. Angiogenesis is a well-proven patho-mechanism in BC. Different angiogenic pathways have been elucidated within the last 20 ;years, among them vascular endothelial growth factor (VEGF), angiopoietin/Tie, matrix metalloproteinases (MMPs), fibroblast growth factor (FGF), thrombospondin 1 (TSP1), and hypoxia-inducible factor (HIF) as the most prominent ones. In order to be able to understand the mechanisms of novel compounds, it is helpful to have a basic knowledge of the relevance of these signaling pathways in the field of BC. Therefore, we not only sum up the majority of clinical studies on anti-angiogenics in BC but also explain the most important pathways responsible for bladder tumor angiogenesis in this chapter.

Many established anti-angiogenics like bevacizumab, sunitinib, sorafenib, aflibercept, pazopanib, and vandetanib have been tested in clinical trials for BC. Furthermore, the pipelines are filled with clinical trials on novel anti-angiogenic drugs like ramucirumab, icrucumab, regorafenib, nintedanib, and many more. However, no compound has yet proven significant single-agent efficacy. Therefore, up to now, no anti-angiogenic drug has been approved for BC therapy.

Consequently, future clinical trials will not only have to test for new anti-angiogenics, but also for different treatment algorithms as well as combination therapies. Although most of the studies showed disappointing overall results, subcohorts had a significant benefit. Therefore, novel approaches should increasingly focus on identifying patient subgroups with the greatest susceptibility to the respective anti-angiogenic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Ajili F, Kacem M, Tounsi H, Darouiche A, Enayfer E, Chebi M, Boubaker S (2012) Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol 36(5):336–342. doi:10.3109/01913123.2012.672847

    Article  PubMed  Google Scholar 

  • Apolo AB (2014) Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma [abstract]. J Clin Oncol 32(Suppl 5S):4501

    Google Scholar 

  • Arkonac BM, Foster LC, Sibinga NE, Patterson C, Lai K, Tsai JC, … Haber E (1998) Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem 273(8):4400–4405

    Google Scholar 

  • Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, … Zigeuner R (2016) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. doi:10.1016/j.eururo.2016.05.041

    Google Scholar 

  • Badr S, Salem A, Yuosif AH, Awadallah H, Awed N, Bakr A (2013) Hypoxia inducible factor-1alpha and microvessel density as angiogenic factors in bilharzial and non-bilharzial bladder cancer. Clin Lab 59(7–8):805–812

    PubMed  Google Scholar 

  • Benoit T, Keller EX, Wolfsgruber P, Hermanns T, Gunthart M, Banzola I, … Poyet C (2015) High VEGF-D and low MMP-2 serum levels predict nodal-positive disease in invasive bladder cancer. Med Sci Monit 21:2266–2274. doi:10.12659/MSM.894383

    Google Scholar 

  • Bertz S, Abee C, Schwarz-Furlan S, Alfer J, Hofstadter F, Stoehr R, … Gaumann AK (2014). Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer. Virchows Arch 465(6):687–695. doi:10.1007/s00428-014-1672-9

    Google Scholar 

  • Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87(21):1603–1612

    Article  CAS  PubMed  Google Scholar 

  • Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S (2004) Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 36(3):401–405

    Article  PubMed  Google Scholar 

  • Chai CY, Chen WT, Hung WC, Kang WY, Huang YC, Su YC, Yang CH (2008) Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 61(5):658–664. doi:10.1136/jcp.2007.050666

    Article  PubMed  Google Scholar 

  • Chaudhary R, Bromley M, Clarke NW, Betts CD, Barnard RJ, Ryder WD, Kumar S (1999) Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 19(4C):3479–3484

    CAS  PubMed  Google Scholar 

  • Cheng CC, Guan SS, Yang HJ, Chang CC, Luo TY, Chang J, Ho AS (2016) Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer. J Biomed Sci 23:18. doi:10.1186/s12929-016-0219-6

    Article  PubMed  PubMed Central  Google Scholar 

  • Chesney JA, Mitchell RA (2015) 25 years on: a retrospective on migration inhibitory factor in tumor angiogenesis. Mol Med 21(Suppl 1):S19–S24. doi:10.2119/molmed.2015.00055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chikazawa M, Inoue K, Fukata S, Karashima T, Shuin T (2008) Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology 75(6):335–345. doi:10.1159/000164218

    Article  CAS  PubMed  Google Scholar 

  • Choudhary S, Hegde P, Pruitt JR, Sielecki TM, Choudhary D, Scarpato K, … Taylor JA 3rd (2013) Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis 34(12):2891–2899. doi:10.1093/carcin/bgt239

    Google Scholar 

  • Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, … Kantoff PW (2012) Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30(5):507–512. doi:10.1200/JCO.2011.37.7002

    Google Scholar 

  • Deniz H, Karakok M, Yagci F, Guldur ME (2010) Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol 42(1):103–107. doi:10.1007/s11255-009-9590-5

    Article  CAS  PubMed  Google Scholar 

  • Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F, Kandemir B (2009) Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205(12):854–857. doi:10.1016/j.prp.2009.07.015

    Article  CAS  PubMed  Google Scholar 

  • Du Z, Hou S (2003) The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 170(5):2000–2003. doi:10.1097/01.ju.0000091879.18156.22

    Article  CAS  PubMed  Google Scholar 

  • Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Mellon JK (2001) Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 7(11):3450–3456

    CAS  PubMed  Google Scholar 

  • Feng C, Wang L, Ding G, Jiang H, Ding Q, Wu Z (2015) BLCA1 expression is associated with angiogenesis of bladder cancer and is correlated with common pro-angiogenic factors. Int J Clin Exp Med 8(9):16259–16265

    PubMed  PubMed Central  Google Scholar 

  • Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Bajorin DF (2010) Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28(8):1373–1379. doi:10.1200/JCO.2009.25.3922

    Article  CAS  PubMed  Google Scholar 

  • Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, … Sonpavde G (2013) Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11(2):175–181. doi:10.1016/j.clgc.2012.10.001

    Google Scholar 

  • Gao Y, Wu K, Chen Y, Zhou J, Du C, Shi Q, … Guo P (2015) Beyond proliferation: KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription. Oncotarget 6(41):43791–43805. doi:10.18632/oncotarget.6101

    Google Scholar 

  • Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, … Eskens FA (2006) A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 17(8):1320–1327. doi:10.1093/annonc/mdl102

    Google Scholar 

  • Goddard JC, Sutton CD, Jones JL, O’Byrne KJ, Kockelbergh RC (2002) Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. Eur Urol 42(5):464–468

    Article  PubMed  Google Scholar 

  • Goddard JC, Sutton CD, Furness PN, O’Byrne KJ, Kockelbergh RC (2003) Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 9(7):2583–2586

    PubMed  Google Scholar 

  • Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, Stopeck AT (2008) A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113(12):3420–3429. doi:10.1002/cncr.23953

    Article  CAS  PubMed  Google Scholar 

  • Gravas S, Bosinakou I, Kehayas P, Giannopoulos A (2004) Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol Int 73(2):173–177. doi:10.1159/000079700

    Article  CAS  PubMed  Google Scholar 

  • Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, … Hussain M (2014) Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 120(5):692–701. doi:10.1002/cncr.28477

    Google Scholar 

  • Guan KP, Ye HY, Yan Z, Wang Y, Hou SK (2003) Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 61(4):719–723

    Article  PubMed  Google Scholar 

  • Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM (2014) The evolving understanding of microRNA in bladder cancer. Urol Oncol 32(1):41 e31-40. doi:10.1016/j.urolonc.2013.04.014

    Article  PubMed  Google Scholar 

  • Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, … Hoosier Oncology Group (2011) Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 29(12):1525–1530. doi:10.1200/JCO.2010.31.6067

    Google Scholar 

  • Herrmann E, Bogemann M, Bierer S, Eltze E, Toma MI, Kopke T, … Wulfing C (2007) The role of the endothelin axis and microvessel density in bladder cancer – correlation with tumor angiogenesis and clinical prognosis. Oncol Rep 18(1):133–138

    Google Scholar 

  • Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, … Dinney CP (2000a) The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6(12):4866–4873

    Google Scholar 

  • Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, … Dinney CP (2000b) Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60(8):2290–2299

    Google Scholar 

  • Ioachim E, Michael M, Salmas M, Michael MM, Stavropoulos NE, Malamou-Mitsi V (2006) Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int 77(3):255–263. doi:10.1159/000094819

    Article  CAS  PubMed  Google Scholar 

  • Johnson AM, O’Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE (2008) Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol 8:7. doi:10.1186/1471-2490-8-7

    Article  PubMed  PubMed Central  Google Scholar 

  • Ke HL, Wei YC, Yang SF, Li CC, Wu DC, Huang CH, Wu WJ (2008) Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. Int J Urol 15(3):200–205. doi:10.1111/j.1442-2042.2007.01978.x

    Article  CAS  PubMed  Google Scholar 

  • Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25–41. doi:10.1038/nrc3817

    Article  CAS  PubMed  Google Scholar 

  • Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL (2013) Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 33(6):2381–2390

    CAS  PubMed  Google Scholar 

  • Kozakowska M, Dobrowolska-Glazar B, Okon K, Jozkowicz A, Dobrowolski Z, Dulak J (2016) Preliminary analysis of the expression of selected proangiogenic and antioxidant genes and MicroRNAs in patients with non-muscle-invasive bladder cancer. J Clin Med 5(3). doi:10.3390/jcm5030029

    Google Scholar 

  • Krege S (2014) Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int 113:429–436

    Article  CAS  PubMed  Google Scholar 

  • Laloglu E, Aksoy H, Aksoy Y, Ozkaya F, Akcay F (2016) The determination of serum and urinary endocan concentrations in patients with bladder cancer. Ann Clin Biochem. doi:10.1177/0004563216629169

    PubMed  Google Scholar 

  • Lawler PR, Lawler J (2012) Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2(5):a006627. doi:10.1101/cshperspect.a006627

    Article  PubMed  PubMed Central  Google Scholar 

  • Mazzola CR, Chin J (2015) Targeting the VEGF pathway in metastatic bladder cancer. Expert Opin Investig Drugs 24(7):913–927. doi:10.1517/13543784.2015.1041588

    Article  CAS  PubMed  Google Scholar 

  • Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, … Bar-Eli M (2003) Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9(8):3167–3175

    Google Scholar 

  • Miyajima A, Kikuchi E, Kosaka T, Oya M (2009) Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer. Rev Recent Clin Trials 4(2):75–78

    Article  CAS  PubMed  Google Scholar 

  • Miyake M, Fujimoto K, Anai S, Ohnishi S, Kuwada M, Nakai Y, … Hirao Y (2011) Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol Rep 25(3):653–660. doi:10.3892/or.2010.1125

    Google Scholar 

  • Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, … Salvioni R (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 13(8):810–816. doi:10.1016/S1470-2045(12)70294-2

    Google Scholar 

  • Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, … Mariani L (2014). Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. Br J Cancer 110(1):26–33. doi:10.1038/bjc.2013.719

    Google Scholar 

  • Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa S (2005) Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 95(4):660–663. doi:10.1111/j.1464-410X.2005.05358.x

    Article  CAS  PubMed  Google Scholar 

  • Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N., … Lee, S. W. (2004) HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64(15):5283–5290. doi:10.1158/0008-5472.CAN-04-0925

    Google Scholar 

  • Petrylak DP (2016) Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase ii trial. J Clin Oncol 34:1500–1509

    Article  CAS  PubMed  Google Scholar 

  • Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, … Vaishampayan U (2013) A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 11(4):477–483. doi:10.1016/j.clgc.2013.05.005

    Google Scholar 

  • Pinto A, Redondo A, Zamora P, Castelo B, Espinosa E (2010) Angiogenesis as a therapeutic target in urothelial carcinoma. Anti-Cancer Drugs 21(10):890–896. doi:10.1097/CAD.0b013e32833e83b2

    Article  CAS  PubMed  Google Scholar 

  • Powles T (2016) PLUTO: a randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours [abstract]. J Clin Oncol 34(Suppl 2S):430

    Article  Google Scholar 

  • Przybylski M (2009) A review of the current research on the role of bFGF and VEGF in angiogenesis. J Wound Care 18(12):516–519. doi:10.12968/jowc.2009.18.12.45609

    Article  CAS  PubMed  Google Scholar 

  • Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, … DeCensi A (2016) Prognostic significance of VEGF after twenty-year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 9(6):437–444. doi:10.1158/1940-6207.CAPR-15-0345

    Google Scholar 

  • Qazi BS, Tang K, Qazi A (2011) Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflamm 2011:908468. doi:10.4061/2011/908468

    Article  Google Scholar 

  • Quentin T, Schlott T, Korabiowska M, Kathei N, Zoller G, Glaser F, Kunze E (2004) Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 24(5A):2745–2756

    CAS  PubMed  Google Scholar 

  • Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, … Detmar M (2013) Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73(3):1097–1106. doi:10.1158/0008-5472.CAN-12-1855

    Google Scholar 

  • Sankhwar M, Sankhwar SN, Abhishek A, Rajender S (2015) Clinical significance of the VEGF level in urinary bladder carcinoma. Cancer Biomark 15(4):349–355. doi:10.3233/CBM-150478

    Article  CAS  PubMed  Google Scholar 

  • Seront E, Rottey S, Sautois B, Kerger J, D’Hondt LA, Verschaeve V, … Machiels JP (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 23(10):2663–2670. doi:10.1093/annonc/mds057

    Google Scholar 

  • Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, … Lotan Y (2010) Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 183(5):1744–1750. doi:10.1016/j.juro.2010.01.018

    Google Scholar 

  • Sheryka E, Wheeler MA, Hausladen DA, Weiss RM (2003) Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 62(1):162–166

    Article  PubMed  Google Scholar 

  • Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, Oya M (2011) Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology 77(4):1009.e19–1009.e25. doi:10.1016/j.urology.2010.11.002

    Article  Google Scholar 

  • Sonpavde G, Bellmunt J (2016) Bladder cancer: angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol 13(6):306–307. doi:10.1038/nrurol.2016.69

    Article  CAS  PubMed  Google Scholar 

  • Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, … Moore MJ (2011) A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 29(5):1045–1049. doi:10.1007/s10637-010-9408-4

    Google Scholar 

  • Suzuki K, Morita T, Tokue A (2005) Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol 12(2):152–158. doi:10.1111/j.1442-2042.2005.01010.x

    Article  CAS  PubMed  Google Scholar 

  • Szarvas T, Jager T, Totsch M, vom Dorp F, Kempkensteffen C, Kovalszky I, … Rubben H (2008) Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 14(24):8253–8262. doi:10.1158/1078-0432.CCR-08-0677

    Google Scholar 

  • Szarvas T, Jager T, Droste F, Becker M, Kovalszky I, Romics I, … Rubben H (2009) Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 15(2):193–201. doi:10.1007/s12253-008-9107-z

    Google Scholar 

  • Szarvas T, Laszlo V, Vom Dorp F, Reis H, Szendroi A, Romics I, … Ergun S (2012) Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients’ prognosis in bladder cancer. Int J Cancer 130(12):2922–2929. doi:10.1002/ijc.26343

    Google Scholar 

  • Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, … Gandara DR (2010) Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 76(4):923–926. doi:10.1016/j.urology.2010.04.025

    Google Scholar 

  • Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, … Hurwitz HI (2013) A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med 2(3):316–324. doi:10.1002/cam4.65

    Google Scholar 

  • Wieczorek E, Jablonowski Z, Tomasik B, Konecki T, Jablonska E, Gromadzinska J, … Reszka E (2015) MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer. Clin Biochem 48(18):1235–1240. doi:10.1016/j.clinbiochem.2015.07.021

    Google Scholar 

  • Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, … Gill PS (2006) Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175(4):1245–1252. doi:10.1016/S0022-5347(05)00736-6

    Google Scholar 

  • Yang CC, Chu KC, Yeh WM (2004) The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22(1):1–6. doi:10.1016/S1078-1439(03)00015-2

    Article  PubMed  Google Scholar 

  • Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, … Koh GY (2011) Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 10:36. doi:10.1186/1476-4598-10-36

    Google Scholar 

  • Yang J, Yang Q, Yu S, Zhang X (2015) Endocan: a new marker for cancer and a target for cancer therapy. Biomed Rep 3(3):279–283. doi:10.3892/br.2015.438

    PubMed  PubMed Central  Google Scholar 

  • Yu G, Yao W, Xiao W, Li H, Xu H, Lang B (2014) MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res 33:779. doi:10.1186/s13046-014-0115-4

    Article  PubMed  PubMed Central  Google Scholar 

  • Zaravinos A, Volanis D, Lambrou GI, Delakas D, Spandidos DA (2012) Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep 28(4):1159–1166. doi:10.3892/or.2012.1948

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Ludwig-Maximilians-University, Marchioninistr. 15, Campus Großhadern, Munich, 81377, Germany

    Gerald Bastian Schulz & Alexander Karl

Authors
  1. Gerald Bastian Schulz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Karl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald Bastian Schulz .

Editor information

Editors and Affiliations

  1. Tumor Biology Center, Freiburg, Baden-Württemberg, Germany

    Dieter Marmé

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Schulz, G.B., Karl, A. (2017). The Value of Anti-angiogenics in Bladder Cancer Therapy. In: Marmé, D. (eds) Tumor Angiogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-31215-6_36-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31215-6_36-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31215-6

  • Online ISBN: 978-3-319-31215-6

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation